好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effectiveness and Safety of Low-Sodium Oxybate in Participants With Narcolepsy or Idiopathic Hypersomnia: Top-line Results From the Phase 4 DUET Study
General Neurology
P10 - Poster Session 10 (5:00 PM-6:00 PM)
2-008

To evaluate effectiveness and safety of low-sodium oxybate (LXB; Xywav®) on excessive daytime sleepiness (EDS) in narcolepsy or idiopathic hypersomnia (IH), sleep architecture and sleep disruption based on polysomnography (narcolepsy cohort) and additional symptoms (IH cohort).

Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, open-label, multiple-cohort study (NCT05875974). 

DUET comprised a screening period (including 2-week washout for current oxybate users), 8-day baseline (BL) period, 2- to 8-week LXB titration period, 2-week stable-dose period, 1- to 2-week end-of-treatment period (EOT), and 2-week safety follow-up. The primary endpoint was change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Key secondary endpoints included, for narcolepsy, change in total sleep stage shifts (deeper to lighter), N3 sleep duration, and number of awakenings, and, for IH, change in Idiopathic Hypersomnia Severity Scale (IHSS) score.

Most dosed participants (narcolepsy, N=55; IH, N=46) were female (72.7%; 80.0%) and White (80.0%; 85.0%), respectively. For narcolepsy, least-squares mean (LSM) (SE) changes from BL to EOT for ESS, total shifts from deeper to lighter stages of sleep, N3 sleep duration (minutes), and number of awakenings were −7.7 (0.9), P<0.0001; −13.1 (3.0), P<0.0001; 45.0 (8.8), P<0.0001; and −3.2 (0.9), P=0.0015 (n=34 each), respectively. For IH, LSM (SE) changes in ESS and IHSS were −8.4 (0.7), P<0.0001 (n=40) and −15.5 (1.5), P<0.0001 (n=36), respectively. Treatment-emergent adverse events (TEAEs) were mild or moderate in severity; the three most common TEAEs were nausea, dizziness, and headache. One serious hypoxia event (concurrent with influenza) unrelated to study drug, which resolved, occurred in the IH cohort.

Participants with narcolepsy or IH taking open-label LXB showed improvements in ESS scores, reduced sleep stage shifts, increased deep sleep (N3), and reduced number of awakenings (narcolepsy) and improvements in ESS and IHSS scores (IH).

Authors/Disclosures
Logan D. Schneider, MD (Stanford/VA Alzheimer's Center)
PRESENTER
Dr. Schneider has received personal compensation for serving as an employee of Alphabet, Inc. Dr. Schneider has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Schneider has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Avadel Pharmaceuticals. Dr. Schneider has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Axsome. Dr. Schneider has received intellectual property interests from a discovery or technology relating to health care.
David Plante David Plante has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. David Plante has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Harmony Biosciences. David Plante has received personal compensation in the range of $0-$499 for serving as a Consultant for Aditum Bio. David Plante has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals. David Plante has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. David Plante has received intellectual property interests from a discovery or technology relating to health care. David Plante has received publishing royalties from a publication relating to health care.
Deborah A. Nichols, MS Ms. Nichols has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Ms. Nichols has stock in Jazz Pharmaceuticals.
Teresa Steininger Teresa Steininger has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Teresa Steininger has stock in Jazz Pharmaceuticals.
Douglas S. Fuller (Jazz Pharmaceuticals) Mr. Fuller has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Fuller has stock in Jazz Pharmaceuticals.
Todd Kirby, PhD Dr. Kirby has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Kirby has stock in Jazz Pharmaceuticals.
Sarah Akerman, MD Dr. Akerman has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Akerman has stock in Jazz Pharmaceuticals.
Jessica K. Alexander, PhD (Jazz) Jessica K. Alexander has received personal compensation for serving as an employee of Teva Pharmaceuticals. Jessica K. Alexander has received stock or an ownership interest from Teva Pharmaceuticals.
Chad Ruoff, MD Dr. Ruoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alkermes. Dr. Ruoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Ruoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals. Dr. Ruoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda . The institution of Dr. Ruoff has received research support from Jazz Pharmaceuticals. Dr. Ruoff has received personal compensation in the range of $10,000-$49,999 for serving as a lecturer with CME lectures .
Alyssa Cairns, PhD Dr. Cairns has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Cairns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals.